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Abstract 
Background: Asthma is prone to Th2-mediated chronic airway inflammation. Interleukin-27 (IL-27) is a member of 
the IL-12 family that promotes the differentiation of Th1 cells and inhibits Th2 cells. We use human/mouse CD4+ T 
cells to see whether IL-27 could inhibit IL-4 production in vitro and then observe whether IL-27 administration could 
alleviate allergic airway inflammation in vivo by mice asthma model.
Methods: We isolated and cultured CD4+ T cells from healthy humans and mice to test whether IL-27 could inhibit 
IL-4 production under different conditions. In vivo study, the effect of IL-27 was examined using two types of intra-
nasal (i.n.) administration: low-dose-multiple-times prevention or high-dose-limited-times treatment in murine 
asthma models. The expression levels of signal transducer and activator of transcription-1 (STAT1) and growth arrest 
and DNA damage 45-γ (GADD45γ)/p38 mitogen activated protein kinase (p38 MAPK) in lung tissues were measured 
using qPCR and Western blotting.
Results: In vitro, although IL-27 could inhibit naïve CD4+ T cell differentiate into Th2 cells, but it could not redifferen-
tiate already committed Th2 cells. In vivo, preventative administration of IL-27 attenuated allergic inflammation and 
airway hyperreactivity, whereas treatment group had no significant effect. In the asthma group, the phosphorylation 
of STAT1 was impaired, while GADD45γ and p38 MAPK exhibited no obvious changes. Preventative administration of 
IL-27 could either reverse the impairment of STAT1 or strengthen the expression of GADD45γ and p38 MAPK, whereas 
treatment group had no significant effect.
Conclusions: Preventative administration of IL-27 improved the pathological changes in mouse asthma models via 
both the STAT1 and GADD45γ/p38 MAPK pathways while therapeutic administration of IL-27 had no significant effect, 
which may be due to the presence of already differentiated Th2 cells in asthmatic airways that resist IL-27 inhibition.
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Background
According to the “Hygiene Hypothesis” that has been 
proposed in the early years, the imbalance of Th1 and Th2 
responses in T lymphocytes and the tendency toward a 
Th2 response is the primary driver of airway inflamma-
tion pathogenesis in asthma [1]. Although established Th 
cells exhibit some plasticity, especially under specific cir-
cumstances such as infections, Th cells that have already 
committed to one Th cell fate tend to down-regulate 
their potential to differentiate into other Th cells. For 
example, significant experimental evidence supports the 
theory that committed Th1 cells minimize their potential 
to transcribe the IL-4 gene [2]. For example, the T-box 
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differentiation, possesses the ability to suppress IL-4 gene 
transcription. In addition to T-bet, it has been reported 
that signal transducer and activator of transcription 
(STAT)4, or interferon regulatory factor-1 and -2 (mice 
deficient in Th1-promoting factors) demonstrate the pro-
pensity to mount a Th2-type immune response against 
pathogens [3, 4]. These results clearly demonstrate that 
Th1-promoting factors are critical in suppressing Th2 cell 
differentiation.
IL-27, a member of IL-12 family, is a heterodimeric 
cytokine composed of EBV-induced gene 3 (EBi3) and 
p28, and it is primarily produced by activated mac-
rophages and dendritic cells [5]. Previous data demon-
strated L-27R–deficient mice displayed increased Th2 
production when infected with the parasites Leishmania 
major or Trichuris muris [6]. Transgenic expression of 
IL-27 suppressed TH2 responses induced by Strongyloi-
des venezuelensis [7]. STAT1 is required for immunity 
against bacteria and viruses in mice [8]. Human subjects 
deficient in STAT1 die of bacterial and viral infections at 
an early age [9, 10]. We demonstrated that IL-27, a key 
cytokine in generating immunity against bacterial and 
viral infection, also depends on STAT1 to suppress TH2 
cell differentiation. GADD45γ is a member of a group 
of genes whose transcript levels are increased follow-
ing treatment with DNA-damaging agents. GADD45γ 
is induced during T cell activation and that the level of 
expression is higher in Th1 cells than in Th2 cells [11].
Of note, recent research has indicated that IL-27 can’t 
inhibit already differentiated Th17 cells [12], and our 
previous study indicated CD4+ T cells from asthmatic 
patients resisted IL-27-mediated suppression of IL-4 pro-
duction [13, 14].
The present study aimed to determine whether IL-27 
can inhibit differentiated Th2 cells in vitro. Furthermore, 
we investigated the effects of preventive and therapeutic 
IL-27 administration on the allergic airway inflammation 
in ovalbumin (OVA)-induced asthma mouse models and 
studied whether the effect is related to the STAT1 and 
GADD45γ/p38 MAPK pathways.
Methods
CD4+ T cell culture and IL‑4 protein measurement
For the human CD4+ T cells, peripheral blood mononu-
clear cells (PBMCs) were isolated using Ficoll-Hypaque 
(Histopaque-1077; Sigma-Aldrich, St Louis, MO, USA) 
gradient centrifugation from the 15  mL of peripheral 
blood collected from each healthy volunteer. The CD4+ T 
cells were isolated from the PBMCs by means of magnetic 
bead separation (magnetic cell sorting) with a human 
CD4+ T Cell Isolation Kit (Miltenyi Biotec). We routinely 
obtained greater than 90 % CD4+ T cell purity. The neu-
tralizing conditions contained 0.5 mg/mL of anti-human 
CD3 antibody, 1 mg/mL of anti-human CD28 antibody, 
50 U/mL of rhIL-2, 10 mg/mL of anti-human IFN-γ anti-
body, and 10  mg/mL of anti-human IL-4 antibody. The 
Th2-inducing conditions contained 0.5  mg/mL of anti-
human CD3 antibody, 1  mg/mL of anti-human CD28 
antibody, 50  U/mL of rhIL-2, 10  mg/mL of anti-human 
IFN-γ antibody, and 15  ng/mL of rhIL-4. After a 6-day 
culture period, the resultant cells were washed to remove 
cytokines that were added to prime the CD4+ T cells, 
and the cells were then stimulated overnight with phor-
bol 12-myristate 13-acetate (50  ng/mL) and ionomycin 
(1  mmol/L) to induce cytokine protein synthesis. The 
supernatants were collected, and the IL-4 protein con-
centrations were measured using ELISA. We obtained 
mononuclear cells from the mouse spleens by extracting 
the red cells using a red blood cell lysis buffer (E00016-
1647, eBioscience, San Diego, CA, USA) and continuing 
with the steps used for isolating human PBMCs.
Mice
Six-week-old female C57/BL6 mice (Silaike experimental 
animal limited liability company, Shanghai, China) were 
housed in pathogen-free conditions. All of the animal 
experiments were approved by the Animal Care and Use 
Committee at the Zhongshan Hospital Affiliate of Fudan 
University, Shanghai, China. The protocol (No: B2014-
108) was previously approved by the Institutional Review 
Board at Fudan University.
Reagents
OVA powder was purchased from Sigma-Aldrich (Grade 
V; St Louis, MO, USA). Adjuvant aluminum hydroxide 
(Al(OH)3(Alum)) was obtained from Thermo Fisher Sci-
entific (Waltham, MA, USA). Recombinant human IL-27 
antibody (rhIL-27), recombinant mouse IL27 antibody 
(rmIL-27), recombinant human IL-4 antibody (rhIL-4), 
recombinant mouse IL-4 antibody (rmIL-4), recombi-
nant human IL-2 antibody (rhIL-2), recombinant mouse 
IL-2 antibody, anti-human INF-γ antibody (rmIL-2), 
anti-mouse INF-γ antibody, anti-human IL-4 antibody 
and anti-mouse IL-4 antibody were obtained from R&D 
Systems (Minneapolis, MN, USA). Anti-human CD3 
antibody, anti-mouse CD3 antibody, anti-human CD28 
antibody and anti-mouse CD28 antibody were obtained 
from eBioscience (San Diego, CA, USA). The follow-
ing antibodies were also used: anti-STAT1 antibody 
(SC592; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA); anti-Py-STAT1 antibody (catalog no. 9171; Cell 
Signaling, Boston, MA, USA), anti-GADD45γ antibody 
(ab196774,Abcam,Cambridge,UK), anti-p38 MAPK 
antibody (CST9212, Cell Signaling, Boston, MA, USA), 
and anti-phospho-p38 MAPK antibody (CST9215, Cell 
Signaling, Boston, MA, USA). The concentrations of 
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IL-4, IL-5, and IL-13 were determined using ELISA kits 
(eBioscience).
Ovalbumin‑induced allergic asthma model and prevention 
and treatment regimens
Specific protocols for each mouse model are shown in 
Figs.  2a, 3a, 4a and 5a. Briefly, for the asthma model, 
6-week-old female C57/BL6 mice were sensitized with 
an intraperitoneal injection (i.p.) of 100  µL of phos-
phate-buffered saline (PBS) (Invitrogen, Paisley, Scotland 
or USA) solution containing 100  µg OVA with 2  mg of 
Alum on days 0 and 7. From days 14 to 18, the mice were 
challenged on 5 consecutive days via an intra-nasal (i.n.) 
administration of 100 µg of OVA in 50 µL of PBS under 
light isoflurane anesthesia [15]. In the limited high-dose 
treatment group, the mice were treated i.n. with IL-27 
(1 µg/mouse) once a day following the last 3 days of OVA 
-challenge. In the multiple low-dose prevention group, 
the mice were treated i.n. with IL-27 at two concentra-
tions (25 and 50 ng/mouse) twice a day for 14 days before 
the second OVA sensitization. There were a minimum of 
eight mice in each group.
Analysis of bronchoalveolar lavage (BAL) fluid in asthma 
mice model
The mice were sacrificed within 24 h after the last OVA 
challenge, and a BAL was immediately performed using 
3 × 1 mL of 0.05 mM PBS–EDTA (Calbiochem, Darm-
stadt, Germany) as previously described [16, 17]. The 
cells were recovered through gentle manual aspiration. 
After centrifugation (1200 rpm for 10 min, at 4  °C), the 
supernatant was collected and frozen at −80 °C for IL-5 
and IL-13 assessment by ELISA. The differential cell 
counts were determined from Wright–Giemsa-stained 
cytospins.
Asthma mice model pulmonary histologic staining 
and scoring
After the BAL, the right main bronchus was clamped, 
and the left lung was excised. The left lung was infused 
with 4  % paraformaldehyde and embedded in paraf-
fin. Five-micrometer paraffin sections were stained with 
hematoxylin–eosin (H&E) or periodic acid–Schiff (PAS). 
The right lung was collected and frozen at −80  °C for 
protein assessment using Western blot. The extent of 
peribronchial and inflammatory-cell infiltration around 
the bronchi in the lung tissue was estimated with a score 
calculated by quantification of the peribronchial and 
perivascular inflammatory cells, such as eosinophils, 
lymphocytes, and macrophages, as previously described 
[18]. Briefly, a value of 0 was attributed when no inflam-
matory cells were detectable around the bronchi. A value 
of 1 was attributed when there were occasionally inflam-
matory cells, a value of 2 was used when most bronchi 
were surrounded by a thin layer (one to five cells) of 
inflammatory cells, and a value of 3 was used when most 
bronchi were surrounded by a thick layer (more than five 
cells) of inflammatory cells. The same method was used 
for the perivascular inflammatory cells. Five to seven ran-
domly selected tissue sections were scored per mouse, 
and thus the peribronchial and perivascular inflamma-
tion scores are expressed as a mean value per animal and 
can be compared between the groups in this study. These 
slides were evaluated and scored by two independently 
pathologists.
Measurement of airway hyperreactivity (AHR) in asthma 
mice model
The mice were anesthetized for measurement of their 
pulmonary mechanics (Buxco Electronics, Wilmington, 
NC) 24  h after the last OVA challenge, as previously 
described [19]. Briefly, the mice were anesthetized with 
50  mg/kg of pentobarbital and were wired to measure 
their pulmonary mechanics (BUXCO Electronics). The 
mice were tracheostomized, intubated, and mechani-
cally ventilated at a tidal volume of 0.2  mL and a fre-
quency of 150 breaths/min as previously described [20]. 
The lung resistance (RL) and Dynamic lung compliance 
(Cydn) were measured in response to increasing doses 
(0–20  mg/mL) of aerosolized acetyl-β-methylcholine 
chloride (methacholine) (Sigma-Aldrich).
Measurement of gene expression
The total RNA was isolated using a guanidinium isothi-
ocyanate/chloroform-based technique (TRIZOL, Inv-
itrogen, USA) and was measured at an OD of 260  nm. 
The RNA was subsequently reverse transcribed into 
cDNA with the SuperScript First-strand Synthesis Sys-
tem (Invitrogen, USA). Quantitative RT-PCR was con-
ducted using an ABI 7000 PCR instrument (Eppendorf, 
Hamburg, Germany) with two-stage program param-
eters as follows: 1  min at 95  °C, followed by 40 cycles 
of 5  s at 95  °C and 30  s at 60  °C. The sequences of the 
primer sets used for this analysis were as follows: STAT1, 
5′-TATTCCAGACCAAAGGAAGCAC-3′ (forward [F]) 
and 5′-GAAGGGTGGACTTCAGACACAG-3′ (reverse 
[R]); GADD45-γ, 5′-TCTACGAGTCCGCCAAAGTC-3′ 
([F]) and 5′-GCACTTGCCACTGGTGTAGA-3′ ([R]); 
p38 MAPK, 5′-CTATGGCTCGGTGTGTGCT-3′ ([F]) 
and 5′-GACGCAACTCTCGGTAGGTC-3′ ([R]); and 
mouse glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Sangon, Shanghai, China). The specificity of 
the produced amplification product was confirmed using 
dissociation reaction plots. Each sample was tested in 
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triplicate with quantitative RT-PCR, and there were at 
least three wells for each group.
Statistical analysis
All of the error bars in this report represent SDs. For 
the ELISA or Western blot analyses, the mean ± SD was 
derived from triplicate measurements of one experi-
ment. The pooled data are represented in the figure leg-
ends. Differences between the data sets were analyzed 
using a one-way ANOVA with a Bonferroni post-test to 
determine significance (Prism 5; GraphPad Software, San 
Diego, CA, USA). A P value < 0.05 was considered statis-
tically significant.
Results
Differentiated Th2 cells resist IL‑27‑mediated inhibition 
of IL‑4 production
In our previous study, we found that CD4+ T cells from 
asthmatic patients resisted the suppression of IL-4 pro-
duction mediated by IL-27 [13]. A possible cause for this 
finding is that CD4+ T cells from healthy subjects are 
mostly made up of naive CD4+ T cells, whereas CD4+ T 
cells from allergic asthmatic patients are predominantly 
Th2 cells resulting from repeated exposure to allergen 
stimulation. It is possible that after repeated exposure 
to allergen stimulation, CD4+ T cells in the peripheral 
blood of allergic asthmatic patients develop resistance 
to IL-27-mediated suppression. To examine this hypoth-
esis, we repeatedly primed CD4+ T cells from healthy 
subjects under Th2-inducing conditions. As a control, 
CD4+ T cells from healthy subjects were first primed 
under neutralizing culture conditions (containing anti-
IL-4 and anti-IFN-γ antibodies) and were then primed 
under Th2-inducing conditions. We found that repeated 
Th2 priming enabled CD4+ T cells from healthy subjects 
to resist IL-27–mediated inhibition (Fig. 1a). We verified 
this finding with a murine Th2 differentiation system. We 
showed that murine IL-27 inhibited the differentiation of 
naive CD4+ T cells into Th2 cells but did not inhibit IL-4 
production in differentiated Th2 cells (Fig. 1b). Thus, we 
concluded that differentiated Th2 cells resist IL-27-medi-
ated inhibition of IL-4 production.
Therapeutic intranasal administration of IL‑27 had no 
significant improvement of airway inflammation in an 
OVA‑induced mouse model
Having demonstrated that differentiated Th2 cells resist 
IL-27-mediated inhibition in vitro, we wanted to further 
investigate whether the inhibition effect works in vivo in 
a mouse asthma model. We first administered IL-27 to 
OVA-immunized mice in the last 3 consecutive days of 
treatment (Fig. 2a). IL-27 treatment did not significantly 
attenuate airway inflammation and did not significantly 
decrease the total cell numbers and differential cell 
counts in BALF (Fig.  2b) or the concentration of IL-5 
and IL-13 in BALF (Fig. 2c). Furthermore, there was no 
obvious reduction in the peribronchial and perivascular 
inflammatory infiltration in H&E-stained lung sections 
(Fig.  2d); the inflammatory infiltration level was further 
quantitated via inflammation scores (Fig.  2e). Moreo-
ver, for the methacholine-induced AHR, a hallmark of 
asthma, the IL-27 treatment also offered no significant 
protection (Fig. 2f ). Together, these results demonstrate 
that differentiated Th2 cells in the complex asthma envi-
ronment also resist IL-27-mediated inhibition in  vivo. 
Further, limited high-dose administration of exogenous 
IL-27 in the challenge stage of asthma did not effectively 
suppress Th2-mediated allergic asthma.
Preventative intranasal administration of IL‑27 in an 
OVA‑induced mouse model resulted in significant 
improvement
It is possible that the differentiated Th2 cells mediated 
the lack of improvement of airway inflammation in the 
asthma mouse model following therapeutic intra-nasal 
administration of IL-27. Based on the “Hygiene Hypoth-
esis” in the early years, we propose that the presence of a 
Th1 environment before the asthma challenge may allevi-
ate the onset of asthma in our model. To test this hypoth-
esis, we administered IL-27 to OVA-immunized mice at 
two concentrations (25 and 50 ng/mouse) twice a day for 
7 days before the OVA challenge (after the second OVA 
sensitization) (Additional file  1: Figure S1A), and there 
seemed to be no obvious improvement in the mouse 
asthma model (Additional file 1: Figure S1B, C). Then, we 
changed the intervention timing of the IL-27 administra-
tion. We administered IL-27 to OVA-immunized mice at 
the same concentration twice a day for 14 days before the 
second OVA sensitization (Fig. 3a). Notably, preventative 
i.n. administration of IL-27 before the second OVA sensi-
tization dramatically attenuated airway inflammation, as 
evidenced by significantly decreased total cell numbers 
and differential cell counts, especially the eosinophils 
in BALF (Fig.  3b), as well as reduced peribronchial and 
perivascular inflammatory infiltrates observed in H&E-
stained lung sections (Fig. 3e). Strikingly decreased accu-
mulation of PAS-positive goblet cells was also observed 
in the low dose IL-27 treatment group (Fig. 3d). Consist-
ently, there were diminished BALF concentrations of Th2 
cytokines, such as IL-5 and IL-13, in the IL-27 preven-
tative group (Fig.  3c). More importantly, preventative 
administration of IL-27 caused significant protection 
from methacholine-induced AHR, a hallmark of asthma 
(Fig. 3f ). Together, these results demonstrate that preven-
tative administration of exogenous IL-27 effectively alle-
viates Th2-mediated allergic asthma.
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Therapeutic administration of IL‑27 neither reversed the 
impairment of the STAT1 pathway nor strengthened the 
GADD45γ/p38 MAPK pathway
As demonstrated above, therapeutic administration 
of IL-27 in the challenge stage of asthma did not effec-
tively suppresses Th2-mediated allergic asthma. Con-
sidering that IL-27 promotes the differentiation of Th1 
while inhibiting the differentiation of Th2 via two path-
ways, STAT1 and GADD45γ/p38 MAPK [5, 11], we 
administered IL-27 to OVA-immunized mice in the last 
3 consecutive days (Fig.  4a). We obtained the RNA and 
protein of lung tissues of each group and analyzed them 
using qPCR and Western blot. As shown, our data indi-
cated that in the asthma group, the mRNA expression of 
STAT1, GADD45γand p38 MAPK exhibited no signifi-
cant changes and that IL-27 intervention had no effect on 
STAT1 and GADD45γ but did up-regulate the expression 
of p38 MAPK (Fig.  4b). Consistently, the total protein 
expression of the three proteins exhibited correspond-
ing changes (Fig.  4c, d). Simultaneously, the changes in 
the phosphorylation level of each protein were notable. 
In the asthma group, the phosphorylation level of STAT1 
was significantly impaired, while p38 MAPK exhibited no 
obvious changes (there was a slight up-regulation). Inter-
estingly, after the IL-27 treatment, the phosphorylation 
levels of the two proteins were significantly down-regu-
lated. All of the results suggested that the inflammation 
existing in the asthma model mainly impaired the phos-
phorylation of the STAT1 protein, which resulted in the 
impairment of the STAT1 pathway, and had no obvious 
effect on the GADD45γ/p38 MAPK pathway. Thera-
peutic administration of IL-27 could neither reverse the 
Fig. 1 Repeated exposure to TH2-inducing conditions induces IL-27 resistance. a ELISA analysis of IL-4 produced by healthy human CD4+ T cells 
subjected to two rounds of priming. b ELISA analysis of IL-4 produced by mouse CD4+ T cells primed as indicated. Error bars and statistical analyses 
are described in the “Methods” section. *P < 0.05, **P < 0.01, ***P < 0.001. The data represent more than three independent experiments with similar 
results
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Fig. 2 Therapeutic intranasal administration of IL-27 does not result in significant improvement of airway inflammation in an OVA-induced mouse 
model. a Protocol of OVA-induced allergic asthma and IL-27 administration. b The total cell number and the differential cell counts in bronchoalveo-
lar lavage fluid (BALF). The total cell number and the differential cell counts had no significant difference in IL-27 treated group. c The concentrations 
of Th2 cytokines in BALF were measured by ELISA. IL-5 and IL-13 level was not markedly changed in IL-27 treated group. d Representative photomi-
crographs of lung sections stained with H&E were examined. There was no improvement of inflammation around airway and vessels in IL-27 treated 
group. e The inflammation scores of peribronchial and perivascular inflammation cells didn’t decreased in IL-27 treated group. f AHR was measured 
by invasive measurement of lung resistance in response to increasing concentrations of methacholine. IL-27 treatment had no improvement in 
lung resistance. The columns and error bars represent the mean and SEM (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. Similar results were 
obtained in at least six independent experiments
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impairment of the STAT1 pathway nor strengthen the 
GADD45γ/p38 MAPK pathway.
Preventative administration of IL‑27 strengthened 
both the STAT1 and GADD45γ/p38 MAPK pathways
In the last section, we verified that the impairment of 
the STAT1 and GADD45γ/p38 MAPK pathways had 
no effect on IL-27-mediated changes in the treatment 
group. Next, we further investigated whether the signifi-
cant effect of IL-27 in the preventative group was related 
to the STAT1 and GADD45γ/p38 MAPK pathways. As 
per the protocol, we administered IL-27 i.n. to OVA-
immunized mice before the OVA sensitization and sac-
rificed the mice before the OVA challenge (Fig. 5a). Next, 
we obtained the mRNA and protein of the lung tissues 
of each group for qPCR and Western blotting. The pre-
ventative administration of IL-27 obviously up-regulated 
the phosphorylation levels of the STAT1 and p38 MAPK 
proteins and the total protein of GADD45γin a dose-
independent way, which was key for the activation of the 
STAT1 and GADD45γ/p38 MAPK pathways (Fig. 4c, d). 
In contrast, there was no significant up-regulation of the 
total protein and mRNA expression of STAT1 and p38 
MAPK (Fig.  5b, c). These results suggest that preventa-
tive administration of IL-27 before OVA sensitization can 
either reverse the impairment of the STAT1 pathway or 
strengthen the GADD45γ/p38 MAPK pathway, presum-
ably promoting Th1 differentiation and alleviating Th2-
mediated allergic asthma.
Discussion
IL-27, as a pleiotropic cytokine, works in promoting Th1 
differentiation, whereas inhibiting Th2 differentiation 
[5]. Our study demonstrated IL-27 could suppress naïve 
CD4+ T cells different into Th2 cells, but not already 
committed Th2 cells’ redifferentiation in  vivo [13]. We 
further administrated IL-27 intro-nasal to see whether 
IL-27 has the capacity to alleviate airway inflammation 
in asthma mice model. To our surprise, preventative 
administration of IL-27 via nose improved the pathologi-
cal symptoms of OVA-induced asthmatic mice, but not 
the therapeutic treated group. STAT1 phosphorylation 
was impaired in the lung of mice in asthmatic condition. 
IL-27 was found to reverse STAT1 phosphorylation and 
strengthen GADD45/p38 MAPK pathway if it was given 
in a preventative way.
The inherent stability of Th2 poses a significant barrier 
to treating allergic diseases. Some research groups have 
previously studied the association between IL-27 and 
several Th2-mediated inflammatory diseases. L-27R–
deficient mice displayed increased Th2 production when 
infected with the parasites of Leishmania major or Tri-
churis muris [6], and transgenic expression of IL-27 
suppressed the Th2 responses induced by Strongyloides 
venezuelensis [7]. In a murine model of collagen-induced 
arthritis (CIA), short-term administration of IL-27 at the 
onset of the disease significantly attenuated the disease 
severity [21]. However, in another experimental arthritis 
model of proteoglycan-induced arthritis, it appears that 
IL-27 played a pro-inflammatory role [22].
Reports about the role of IL-27 in asthma are mini-
mal. Yoshimoto and his team [7] reported that IL-27 sup-
pressed Th2 cell development and Th2 cytokine production 
from polarized Th2 cells and that IL-27 could significantly 
improve the pathologic symptoms through large-dose i.n. 
administration during the OVA-challenge stage in an OVA-
induced mouse asthma model. However, in our IL-27 treat-
ment group, large-dose i.n. administration of IL-27 during 
the last 3 days of the OVA-challenge stage generated no sig-
nificant improvement in the pathologic symptoms (Fig. 2). 
The differing results between Yoshimoto’s group and our 
study may be due to the difference between the protocols of 
our mouse asthma model (the former study used an asthma 
model of 10 days, and ours is 19 days), which may result in 
the different severity of Th2 inflammation.
In the present study, we proved that IL-27 did not 
inhibit the already differentiated Th2 cells in both mouse 
and human systems in vitro (Fig. 1) This might result in 
the inability of therapeutic i.n. administration of IL-27 to 
improve the pathological asthma symptoms. We propose 
that strengthening a Th1 environment before the asthma 
challenge model may alleviate the onset of asthma. To 
verify this hypothesis, we set up a low-dose preventative 
model with multiple administrations. In the beginning, 
we administered IL-27 for 7 days after OVA sensitization 
but before the OVA challenge and obtained no significant 
(See figure on previous page.) 
Fig. 3 Preventative intranasal administration of IL-27 results in obvious improvement in an OVA-induced mouse model. a Protocol of OVA-induced 
allergic asthma and IL-27 administration. b The total cell number and the differential cell counts in bronchoalveolar lavage fluid (BALF). The total cell 
number and eosinophil number were decreased in IL-27 treated group. c The concentrations of Th2 cytokines in BALF were measured by ELISA. IL-5 
and IL-13 level was lower in IL-27 treated group than OVA group. d Representative photomicrographs of lung sections stained with H&E or PAS were 
examined. IL-27 preventative treatment alleviated lung inflammation. e The inflammation scores of peribronchial and perivascular inflammation cells 
were markedly lower in IL-27 preventatively treated group. f AHR was measured by invasive measurement of lung resistance in response to increasing 
concentrations of methacholine. IL-27 preventatively treated group was seen the improvement of lung resistance. The columns and error bars represent 
the mean and SEM (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. Similar results were obtained in at least six independent experiments
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improvement in asthma symptoms (Additional file 1: Fig-
ure S1). We speculated that the failure effect may result 
from the inflammatory environment that had been built 
after the OVA sensitization. Thus, we changed the timing 
of the IL-27 administration and administered IL-27 for 
14  days before the OVA sensitization (Fig.  3a). Notably, 
this protocol significantly improved the pathological 
change of asthma (Fig. 3).
Fig. 4 The STAT1 and GADD45γ/p38 MAPK pathways remain impairment in the IL-27 treatment groups. a Protocol of OVA-induced allergic asthma 
and IL-27 administration. b The mRNA expression of STAT1, GADD45-γ and p38 MAPK by qPCR. c The protein expression of STAT1, GADD45γ and p38 
MAPK by Western blot. In IL-27 treated group, p-STAT1, p-p38MAPK were still impaired compared with PBS group, while GADD45γ had no markedly 
difference. d Densitometer measurements of pSTAT1/GAPDH, GADD45γ/GAPDH and p38 MAPK/GAPDH. IL-27 treatment had no improvement in 
the already impaired signal pathway.(GAPDH expression was acted as internal reference.) The columns and error bars represent the mean and SEM 
(n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. Similar results were obtained in at least three independent experiments
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Fig. 5 The STAT1 and GADD45γ/p38 MAPK pathways are up-regulated in the IL-27 prevention groups. a Protocol of OVA-induced allergic asthma 
and IL-27 administration. b The mRNA expression of STAT1, GADD45-γ and p38 MAPK by qPCR. It showed IL-27 preventative treatment reverse the 
impaired STAT1 and strengthen GADD45-γ expression as well. c The protein expression of STAT1, GADD45-γ and p38 MAPK by Western blot. It shows 
IL-27 preventative treatment reverse the impaired p-STAT1 and strengthen GADD45-γ/p38 MAPK protein expression as well. d Densitometer meas-
urements of pSTAT1/GAPDH, GADD45-γ/GAPDH and p38 MAPK/GAPDH. GAPDH expression was acted as internal reference. The columns and error 
bars represent the mean and SEM (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. Similar results were obtained in at least three independent 
experiments
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STAT1 is particularly critically important for IL-27 
signaling, leading to the up-regulation of ICAM-1 and 
T-bet expression in naive CD4+ T cells and, conse-
quently, to Th1 differentiation [23]. Independently of 
STAT1, IL-27 also induced GADD45 expression, activat-
ing p38 MAPK [11], followed by augmentation of T-bet 
expression. Therefore, we further investigated whether 
the effect of IL-27 intervention was related to the two 
pathways by analyzing the mRNA and protein expres-
sion of STAT1, GADD45γ and p38 MAPK. We found 
that the inflammation existing in the asthma model 
mainly impaired the phosphorylation of the STAT1 pro-
tein, which resulted in the impairment of the STAT1 
pathway, and had no obvious effect on the GADD45γ/
p38 MAPK pathway. The large-dose therapeutic model 
of IL-27 with few administrations could neither reverse 
the impairment of the STAT1 pathway nor strengthen 
the GADD45γ/p38 MAPK pathway. In contrast, the low-
dose preventative administration of IL-27 with multiple 
administrations could either reverse the impairment of 
the STAT1 pathway or strengthen the GADD45γ/p38 
MAPK pathway and improve the pathologic symptoms 
of asthma. These results fully demonstrated the effect of 
IL-27 intervention through the STAT1 and GADD45γ/
p38 MAPK pathways; Furthermore, these findings also 
suggest that IL-27 primarily promotes the differentiation 
of Th1 through STAT1 pathways in vivo.
Different methods of IL-27 administration resulted in 
two absolutely different effects. We propose that the key 
point is the timing of the administration of IL-27. In the 
treatment group, IL-27 was administered during the last 
3  days of OVA challenge when the CD4+ T cells were 
already almost differentiated into Th2 cells, and the dif-
ferentiated Th2 cells resisted the inhibitory effect of 
IL-27. In the prevention group, IL-27 was administered 
before OVA sensitization when the CD4+ T cells were 
largely naïve and could be promoted to differentiate into 
Th1 cells by IL-27, supporting an environment of Th1 
cells before the asthma challenge could alleviate the onset 
of an asthma attack.
Conclusions
In conclusion, preventative administration of IL-27 could 
either reverse the impairment of STAT1 or strengthen 
the expression of GADD45γ/p38 MAPK which leads to 
alleviate airway inflammation and improve AHR in asth-
matic mice. Lack of effects in the therapeutic administra-
tion group contributed to already differentiated Th2 cells 
existing in asthmatic airways that resist to IL-27-medi-
ated Th2 differentiation.
Our pilot study indicates a promising role for IL-27, a 
pleiotropic cytokine,in alleviating the pathogenesis of 
mouse asthma with the proper administration route and 
timing. This research sheds light on cytokine treatment, 
especially that involving IL-27, which has the potential 
to be used as an intervention in asthma prevention and 
management in the future.
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IL-27 after OVA sensitization had no improvement in an OVA-induced 
mouse model. (A) Protocol of OVA-induced allergic asthma and IL-27 
administration. (B) The total cell number counts in bronchoalveolar lavage 
fluid (BALF). (C) Representative photomicrographs of lung sections stained 
with H&E. The Columns and error bars represent mean and SEM (n = 6 per 
group). *P < 0.05, **P < 0.01, ***P < 0.001. Similar results were obtained 
in at least six independent experiments. Figure S2. mRNA expression of 
GATA3 and T-bet of lung mononuclear cells by real-time PCR. A. GATA3 
expression of lung mononuclear cells from PBS, OVA, OVA + IL-27 50 ng, 
OVA + IL-27 100 ng groups (HPRT mRNA level as an internal standard). B. 
T-bet expression of lung mononuclear cells from PBS, OVA, OVA + IL-27 
50 ng, OVA + IL-27 100 ng groups (HPRT mRNA level as an internal stand-
ard). **P < 0.01 means significant difference.
Page 12 of 12Su et al. J Transl Med  (2016) 14:283 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
References
 1. Huang H. Suppressing allergic immune responses. Front Biosci. 
2011;3:864–70.
 2. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, Guo L, Yagi R, Yamane 
H, Punkosdy G, Feigenbaum L, Zhao K, Paul WE. The transcription factor 
T-bet is induced by multiple pathways and prevents an endogenous Th2 
cell program during Th1 cell responses. Immunity. 2012;37:660–73.
 3. Hida S, Tadachi M, Saito T, Taki S. Negative control of basophil expan-
sion by IRF-2 critical for the regulation of Th1/Th2 balance. Blood. 
2005;106:2011–7.
 4. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Udaka K, Ueno H. Mice 
lacking the IFN-γ receptor or fyn develop severe experimental autoim-
mune uveoretinitis characterized by different immune responses. Immu-
nogenetics. 2005;57:337–43.
 5. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matusi M, Mizuguchi 
J, Yoshimoto T. A role for IL-27 in early regulation of Th1 differentiation. J 
Immunol. 2005;175:2191–200.
 6. Artis D, Villarino A, Silverman M, He W, Thornton EM, Mu S, Summer S, 
Covey TM, Huang E, Yoshida H, Koretzky G, Goldschmidt M, Wu GD, de 
Sauvage F, Miller HR, Saris CJ, Scott P, Hunter CA. The IL-27 receptor (WSX-
1) is an inhibitor of innate and adaptive elements of type 2 immunity. J 
Immunol. 2004;173:5626–34.
 7. Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell 
development and Th2 cytokines production from polarized Th2 cells: a 
novel therapeutic way for Th2-mediated allergic inflammation. J Immu-
nol. 2007;179:4415–23.
 8. Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, 
et al. Impairment of mycobacterial but not viral immunity by a germline 
human STAT1 mutation. Science. 2001;293:300–3.
 9. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah 
S, et al. Impaired response to interferon-α/β and lethal viral disease in 
human STAT1 deficiency. Nat Genet. 2003;33:388–91.
 10. Chen Z, Zhu R, Bai L, Bai C. Downregulation of aquaporin 5, induced by 
vector-based short hairpin RNA, and its effect on MUC5AC gene expres-
sion in human airway submucosal gland cells. Respir Physiol Neurobiol. 
2006;152(2):197–203.
 11. Lu B, Yu H, Chow C, Li B, Zheng W, Davis RJ, Flavell RA. GADD45 mediates 
the activation of the p38 and JNK MAP kinase pathways and cytokine 
production in effector TH1 cells. Immunity. 2001;14:583–90.
 12. El-behi M, Ciric B, Yu S, Zhang GX, Fitzgerald DC, Rostami A. Differential 
effect of IL-27 on developing versus committed Th17 Cells. J Immunol. 
2009;183:4957–67.
 13. Chen Z, Wang S, Erekosima N, Li Y, Hong J, Qi X, Merkel P, Nagabhush-
anam V, Choo E, Katial R, Alam R, Trikha A, Chu HW, Zhuang Y, Jin M, Bai C, 
Huang H. IL-4 confers resistance to IL-27 mediated suppression on CD4+ 
T cells by impairing signal transducer and activator of transcription 1 
signaling. J Allergy Clin Immunol. 2013;132:912–21.
 14. Chen Zhihong, Wang Xiangdong, Bai Chunxue. Regulation of MUC5AC 
mucin secretion by depletion of AQP5 in SPC-A1 cells. Biochem Biophys 
Res Commun. 2006;342:775–81.
 15. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, Ackerman 
K, Haley K, Galle PR, Szabo SJ, Drazen JM, De Sanctis GT, Glimcher LH. 
Development of spontaneous airway changes consistent with human 
asthma in mice lacking T-bet. Science. 2002;295:336–8.
 16. Cataldo DD, Tournoy KG, Vermaelen K, Munaut C, Foidart JM, Louis R, Noël 
A, Pauwels RA. Matrix metalloproteinase-9 deficiency impairs cellular 
infiltration and bronchial hyperresponsiveness during allergen-induced 
airway inflammation. Am J Pathol. 2002;161:491–8.
 17. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, Shapiro S, 
Lopez-Otin C, Noël A, Cataldo DD. Matrix metalloproteinase-8 deficiency 
promotes granulocytic allergen-induced airway inflammation. J Immu-
nol. 2005;175:2589–97.
 18. Curtis JL, Byrd PK, Warnock ML, Kaltreider HB. Requirement of CD4-
positive T cells for cellular recruitment to the lungs of mice in response to 
a particulate intratracheal antigen. J Clin Invest. 1991;88:1244–54.
 19. Kim HY, Chang YJ, Chuang YT, Lee HH, Kasahara DI, Martin T, et al. T-cell 
immunoglobulin and mucin domain 1 deficiency eliminates airway 
hyperreactivity triggered by the recognition of airway cell death. J Allergy 
Clin Immunol. 2013;132:414–25.
 20. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. 
Essential role of NKT cells producing IL-4 and IL-13 in the development of 
allergen-induced airway hyperreactivity. Nat Med. 2003;9:582–8.
 21. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY. 
Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis. 
2008;67:1474–9.
 22. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune 
response and susceptibility to experimental arthritis. J Immunol. 
2008;180:922–30.
 23. Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T. An 
indispensable role for STAT1 in IL-27-induced T-bet expression but not 
proliferation of naive CD4 T cells. J Immunol. 2004;173:3871–7.
